Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations-Reference-Cited by-同舟云学术

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

Published:2022-06-02 Issue:22 Volume:139 Page:3340-3344
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Tausch Eugen¹,Ljungström Viktor²,Agathangelidis Andreas³⁴,Zapatka Marc⁵^ORCID,Scarfò Lydia³,Jebaraj Billy Michael Chelliah¹,Yosifov Deyan Y.¹⁵^ORCID,Müller Annika¹,Munugalavadla Veerendra⁶,Degenhardt Jeremiah D.⁷,Ghia Paolo³^ORCID,Rosenquist Richard⁸⁹,Stilgenbauer Stephan¹

Affiliation:

1. 1Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University, Ulm, Germany;

2. 2Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;

3. 3Università Vita-Salute San Raffaele and Ospedale San Raffaele, Milan, Italy;

4. 4Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece;

5. 5German Cancer Research Center, Heidelberg, Germany;

6. 6Translational Medicine, Hematology Research and Development, AstraZeneca, South San Francisco, CA;

7. 7Research and Development, Maverick Therapeutics, Brisbane, CA;

8. 8Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; and

9. 9Clinical Genetics, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/139/22/3340/1900277/bloodbld2021014550.pdf

Reference11 articles.

1. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia;Murali;Blood.,2021

2. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia;Furman;N Engl J Med.,2014

3. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial;Jones;Lancet Haematol.,2017

4. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors [abstract];Sharman;Blood.,2014

5. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy;Mato;Blood.,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia;Frontiers in Oncology;2024-02-26

2. Visible-light-induced three-component reactions of α-diazoesters, quinazolinones and cyclic ethers toward quinazoline-based hybrids;Organic & Biomolecular Chemistry;2024

3. Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors;Blood Advances;2023-09-27

4. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer;Molecular Cancer;2023-08-18

5. Rhodium-Catalyzed C–H Activation of 2-Arylquinazolinones and Cyclization with Elemental Sulfur via C–S/S–N Bond Formation to Access 7H-Benzo[4,5]isothiazolo[3,2-b]quinazolinones;Synthesis;2023-08-02